
Scailyte and Geninus announce a strategic partnership to develop a predictive assay for immune-checkpoint inhibitors in Non-Small Cell Lung Cancer patients
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cell genomics provider Geninus, today announce a strategic partnership to develop a patient stratification and predictive platform for Non-Small Cell Lung Cancer (NSCLC).
The companies join their unique expertise in data generation and analysis: Geninus brings a variety of cutting-edge genomic analysis technologies and experienced global R&D specialists, and Scailyte leverages a best-in-class single-cell data analysis platform, ScaiVision, to identify and validate disease-specific molecular biomarkers.
Through the joint venture, Geninus will lead the recruitment of NSCLC patients’ undergoing immune-checkpoint inhibitor (ICI) therapy and the processing of samples at a single-cell precision level, while Scailyte will drive the molecular biomarker discovery studies together with clinical key opinion leaders in the disease area. Following biomarker discovery, Geninus will focus on the prototyping, development and clinical validation of the prognostic assay.
The benefits of these joint efforts are copious: patients suffering from NSCLC will be stratified based on a ICI response-prediction assay, and the clinicians will have tools for an informed therapeutic decision, thereby ensuring a high response rate of patients ultimately selected for ICI. Moreover, new biological and therapeutic approaches could be explored on the basis of molecular markers that define response to ICI.
Manfred Claassen, Prof. Dr., Co-founder of Scailyte commented: “Scailyte’s machine learning models allow unprecedented systematic and thorough screening for biomarker profiles in high dimensional single-cell data. Accounting for approximately 25% of cancer deaths, NSCLC remains the cancer with the highest mortality rate worldwide. Together with Geninus, we aim to develop a non-invasive and accurate molecular prognostic method to identify NSCLC patients responsive to immune-checkpoint inhibitors. I am excited to witness how the assay will help oncologists in making informed decisions for ICI prescription, thereby ensuring a high response rate of patients and reducing the health and economic burden attributed to improper treatments.”
Woong-Yang Park, Prof. Dr., Founder and CEO of Geninus added: “Geninus is a Samsung Genome Institute spinoff, providing clinical genome analysis solutions to precision medicine clinics. Geninus aims to implement single cell genome analysis techniques to facilitate personalized patient care. Immune cell profile of cancer tissues or peripheral blood correlates with clinical responses to immunotherapy. Scailyte’s machine learning model will add value to the single-cell gene expression profile of patients. We hope to provide prognostic methods for immunotherapy response in precision medicine clinics through collaboration with Scailyte.”
About Scailyte
Scailyte AG is a spin-off of ETH Zurich and combines single-cell technologies, high-quality datasets, and machine learning methods to identify disease-specific biomarkers with a focus on oncology and immunology. Scailyte’s proprietary best-in-class data analysis platform (ScaiVision) associates multimodal single-cell datasets with clinical endpoints in order to identify ultra-sensitive biomarker signatures. Thanks to the single-cell resolution and AI-driven approach, ScaiVision is a powerful and cutting-edge approach to precisely diagnose or predict therapy response. Scailyte leverages a broad network of top clinicians to identify disease indications with highly unmet medical needs, and collaborates with global pharmaceutical and biotech companies to translate the novel biomarkers into ultra-sensitive diagnostic applications.
For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.
About Geninus
Geninus provides clinical genome analysis solutions for personalized cancer treatment with targeted therapeutics and immunotherapy in major hospitals in Korea and Japan. Clinical sequencing platform covers information management systems, bioinformatics pipeline, variant annotation, clinical report, and data center as one system. OncoSTATION, a user interface for the clinical sequencing platform, can be installed in hospital information systems. Geninus operates a single-cell genome and spatial transcriptome analysis platform, Celinus, for biomarker discovery. Collaborations with clinicians and pharmaceutical companies enable Celinus to unearth new druggable targets or diagnostic markers in tumor microenvironment cells.
For more information, visit http://www.kr-geninus.com/en/ and connect on social media @LinkedIn.
Recent News
NextGen Omics Boston Conference
Scailyte will be attending the upcoming NextGen Omics Boston conference, taking place on March 30-31
Recent News
Vijay Tiwari is appointed as Chair of the Scientific Advisory Board
Vijay Tiwari is appointed as the Chair of Scailyte's Scientific Advisory Board
Recent News
Endometriosis interview series
We mark Endometriosis Awareness Month, and Scailyte is proud to support this cause with the “Endom
Recent News
Scailyte Announces a Collaboration with Turnstone Biologics
Scailyte Announces Collaboration with Turnstone Biologics to Identify Biomarker Signatures in Solid
Recent News
BIO-Europe Spring 2023
We will be attending the 17th annual BIO-Europe Spring taking place from 20-22 March 2023 in Basel.
Recent News
Deciphering Disease Mechanisms Through Functional Genomics
Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica
Recent News
International Women's Day 2023
Scailyte celebrates International Women’s day and praises all women Scailyters: smart, trailblazin
Recent News
Diana Stoycheva and Sarah Carl at Biomarkers 2023
We are excited to announce our attendance at Oxford Global Conferences' Biomarkers 2023! Our team, i
Recent News
NextGen Omics Boston Conference
Scailyte will be attending the upcoming NextGen Omics Boston conference, taking place on March 30-31
Vijay Tiwari is appointed as Chair of the Scientific Advisory Board
Vijay Tiwari is appointed as the Chair of Scailyte's Scientific Advisory Board
Recent News
Endometriosis interview series
We mark Endometriosis Awareness Month, and Scailyte is proud to support this cause with the “Endom
Scailyte Announces a Collaboration with Turnstone Biologics
Scailyte Announces Collaboration with Turnstone Biologics to Identify Biomarker Signatures in Solid
Recent News
BIO-Europe Spring 2023
We will be attending the 17th annual BIO-Europe Spring taking place from 20-22 March 2023 in Basel.
Deciphering Disease Mechanisms Through Functional Genomics
Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica
Recent News
International Women's Day 2023
Scailyte celebrates International Women’s day and praises all women Scailyters: smart, trailblazin
Diana Stoycheva and Sarah Carl at Biomarkers 2023
We are excited to announce our attendance at Oxford Global Conferences' Biomarkers 2023! Our team, i